Lynparza recommended for approval in EU by CHMP as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
21 September 2020 07:00 BST Lynparza recommended for approval in EU by CHMP as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer Patients treated with Lynparza and bevacizumab lived without diseaseprogression for a median of 37.2 months vs. 17.7 months for bevacizumab alone One in two women with advanced ovarian cancer has an HRD-positive tumour AstraZeneca and MSD's Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment with bevacizumab of patients with